The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Adult and paediatric patients with central nervous system tumours that display an NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options
Central Nervous System Malignancies
Central Nervous System tumours
NTRK gene fusion
SCOUT and NAVIGATE
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Larotrectinib
-
Single arm (Phase I/II)
Adult and paediatric patients with lung cancer that display an NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options
Thoracic Malignancies
Lung Cancers
NTRK gene fusion
NAVIGATE
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Larotrectinib
-
Single arm (Phase I/II)
Adult and paediatric patients with salivary gland tumours that display an NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options
Head and neck cancer
Salivary gland
NTRK gene fusion
NAVIGATE
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Abemaciclib
Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression)
Standard endocrine therapy
Adjuvant treatment in combination with endocrine therapy of adult patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Breast Cancer
Early Breast Cancer
HR+ HER2- node-positive
monarchE
A
ADJUSTMENTS
FINAL SCORE
F1
1
Elacestrant
-
Standard-of-care endocrine therapy
Postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Breast Cancer
Breast Cancer
ER+ HER2-negative, ESR1-mutated
EMERALD
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Pembrolizumab
-
Placebo
Adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC)
Thoracic Malignancies
Non-small-cell Lung Cancer
-
PEARLS/KEYNOTE-091
A
ADJUSTMENTS
FINAL SCORE
F1
1
Sacituzumab govitecan
-
Physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
For patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
Breast Cancer
Breast Cancer
HR-positive HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-)
TROPiCS-02
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Nivolumab
-
Single arm (Phase II)
Treatment of patients 12 years and older with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
CheckMate 142
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Mirvetuximab soravtansine
-
Single arm (Phase II)
-
Gynaecological Malignancies
Epithelial ovarian, fallopian tube or primary peritoneal cancer
FRα positive
SORAYA
2
PRELIMINARY SCORE
OS
7
ADJUSTMENTS
FINAL SCORE
F1
4
Futibatinib
-
Single arm
Treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy
Gastrointestinal Cancers
Intrahepatic cholangiocarcinoma
FGFR2 gene fusion or other rearrangement
FEONIX-CCA2
3
ADJUSTMENTS
FINAL SCORE
F1
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.